The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Distribution of Gefitinib to the Brain Is Limited by P-glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2)-Mediated Active Efflux
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Wen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
Giaccone, G., Herbst, R. S., Manegold, C., Scagliotti, G., Rosell, R., Miller, V., Natale, R. B., Schiller, J. H., von Pawel, J., Pluzanska, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.001 · Cited by 1,716
Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V., Manegold, C., Scagliotti, G., Rosell, R., Oliff, I., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,707
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051918 · Cited by 1,442
ABC transporters in cancer: more than just drug efflux pumps
Fletcher, J. I., Haber, M., Henderson, M. J., & Norris, M. D. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2789 · Cited by 1,018
A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.
Ciardiello, F., & Tortora, G. (2001) · PubMed · Cited by 977
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
Stommel, J. M., Kimmelman, A. C., Ying, H., Nabioullin, R., Ponugoti, A. H., Wiedemeyer, R., Stegh, A. H., Bradner, J. E., Ligon, K. L., Brennan, C., et al. (2007) · Science · doi:10.1126/science.1142946 · Cited by 938 · cited 2×
“, 2007) or due to the complexity of signaling pathways, such as negative feedback mechanisms and up-regulation of alternative pathways (Stommel et al., 2007).”
BackgroundAllen, J. D., van Loevezijn, A., Rademaker-Lakhai, J. M., van der Valk, M., van Tellingen, O., Reid, G., Schellens, J. H. M., Koomen, G., & Schinkel, A. H. (2002) · PubMed · Cited by 814
Phase II Trial of Gefitinib in Recurrent Glioblastoma
Rich, J. N., Reardon, D. A., Peery, T., Dowell, J. M., Quinn, J. A., Penne, K. L., Wikstrand, C. J., Van Duyn, L. B., Dancey, J. E., McLendon, R. E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.110 · Cited by 734
Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases
Löscher, W., & Potschka, H. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.04.006 · Cited by 617
Isolation and characterization of human malignant glioma cells from histologically normal brain
Silbergeld, D. L., & Chicoine, M. R. (1997) · Journal of Neurosurgery · doi:10.3171/jns.1997.86.3.0525 · Cited by 290
Distribution of STI-571 to the Brain Is Limited by P-Glycoprotein-Mediated Efflux
Dai, H., Marbach, P., Lemaire, M., Hayes, M., & Elmquist, W. F. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.045260 · Cited by 273
Self-citationPolli, J. W., Olson, K. L., Chism, J. P., John-Williams, L. S., Yeager, R. L., Woodard, S. M., Otto, V., Castellino, S., & Demby, V. E. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.024646 · Cited by 256
Elkind, N. B., Szentpétery, Z., Apáti, A., Özvegy-Laczka, C., Várady, G., Ujhelly, O., Szabó, K., Homolya, L., Váradi, A., Buday, L., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3303 · Cited by 225
Franceschi, E., Cavallo, G., Lonardi, S., Magrini, E., Tosoni, A., Grosso, D., Scopece, L., Blatt, V, Urbini, B., Pession, A., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603669 · Cited by 211
Davis, F. G., Kupelian, V. A., Freels, S. A., McCarthy, B. J., & Surawicz, T. S. (2001) · Neuro-Oncology · doi:10.1093/neuonc/3.3.152 · Cited by 204
Sarkaria, J. N., Yang, L., Grogan, P. T., Kitange, G. J., Carlson, B. L., Schroeder, M. A., Galanis, E., Giannini, C., Wu, W., Dinca, E. B., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0691 · Cited by 200
Lessons learned in the development of targeted therapy for malignant gliomas
Omuro, A. M. P., Faivre, S., & Raymond, E. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0047 · Cited by 196
P-glycoprotein and Breast Cancer Resistance Protein Influence Brain Distribution of Dasatinib
Chen, Y., Agarwal, S., Shaik, N. M., Chen, C., Yang, Z., & Elmquist, W. F. (2009) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.154781 · Cited by 194
Self-citationKamath, A. V., Wang, J., Lee, F. Y., & Marathe, P. H. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0478-8 · Cited by 191
Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation
Lagas, J. S., van Waterschoot, R. A. B., Sparidans, R. W., Wagenaar, E., Beijnen, J. H., & Schinkel, A. H. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0663 · Cited by 185
Dantzig, A. H., Shepard, R. L., Law, K. L., Tabas, L., Pratt, S., Gillespie, J. S., Binkley, S. N., Kuhfeld, M. T., Starling, J. J., & Wrighton, S. A. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)34974-2 · Cited by 179
Lagas, J. S., van Waterschoot, R. A. B., van Tilburg, V. A. C. J., Hillebrand, M. J., Lankheet, N., Rosing, H., Beijnen, J. H., & Schinkel, A. H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2253 · Cited by 173
Tyrosine kinase inhibitors—ZD1839 (Iressa)
Arteaga, C. L., & Johnson, D. H. (2001) · Current Opinion in Oncology · doi:10.1097/00001622-200111000-00012 · Cited by 172
Role Reversal for Anticancer Agents
Pardee, A. B. (2002) · Cancer Biology & Therapy · doi:10.4161/cbt.1.4.22 · Cited by 165
Appetite and Cancer-Associated Anorexia: A Review
Davis, M. P., Dreicer, R., Walsh, D., Lagman, R. L., & LeGrand, S. B. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.103 · Cited by 155
PTEN-Mediated Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors
Mellinghoff, I. K., Cloughesy, T. F., & Mischel, P. S. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1992 · Cited by 146
Epidermal Growth Factor Receptor Inhibitors in Neuro-oncology: Hopes and Disappointments
Brandes, A. A., Franceschi, E., Tosoni, A., Hegi, M. E., & Stupp, R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1810 · Cited by 145
Oostendorp, R. L., Buckle, T., Beijnen, J. H., van Tellingen, O., & Schellens, J. H. M. (2008) · Investigational New Drugs · doi:10.1007/s10637-008-9138-z · Cited by 137
McKillop, D., Partridge, E. A., Kemp, J. V., Spence, M. P., Kendrew, J., Barnett, S., Wood, P. G., Giles, P. B., Patterson, A. B., Bichat, F., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0329 · Cited by 133
Blakeley, J. O., Olson, J. J., Grossman, S. A., He, X., WEINGART, J. D., & Supko, J. G. (2008) · Journal of Neuro-Oncology · doi:10.1007/s11060-008-9678-2 · Cited by 125
Mukasa, A., Wykosky, J., Ligon, K. L., Chin, L., Cavenee, W. K., & Furnari, F. B. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914356107 · Cited by 83
Lee, G. S., Babakhanian, K., Ramaswamy, M., Prat, A., Wosik, K., & Bendayan, R. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9244-1 · Cited by 76
Culy, C. R., & Faulds, D. M. (2002) · Drugs · doi:10.2165/00003495-200262150-00008 · Cited by 72
Fine, R. L., Chen, J., Balmaceda, C. M., Bruce, J. N., Huang, M., Desai, M., Sisti, M. B., McKhann, G. M., Goodman, R. R., Bertino, J., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2356 · Cited by 67
Wang, S., Guo, P., Wang, X., Zhou, Q. S., & Gallo, J. M. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2070 · Cited by 59
NABTC phase I/II trial of ZD-1839 for recurrent malignant gliomas and unresectable meningiomas
Lieberman, F. S., Cloughesy, T. F., Fine, H. A., Kuhn, J. G., Lamborn, K. R., Malkin, M. G., Robbins, H. I., Yung, W. A., Wen, P. Y., & Prados, M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.1510 · Cited by 58
Gefitinib concentrations in human glioblastoma tissue
Höfer, S., & Frei, K. (2006) · Journal of Neuro-Oncology · doi:10.1007/s11060-006-9257-3 · Cited by 38
Cited by
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
van Tellingen, O., Yetkin-Arik, B., de Gooijer, M. C., Wesseling, P., Wurdinger, T., & de Vries, H. E. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.02.002 · Cited by 1,035
Current Challenges and Opportunities in Treating Glioblastoma
Shergalis, A., Bankhead, A., Luesakul, U., Muangsin, N., & Neamati, N. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014944 · Cited by 849
Sarkaria, J. N., Hu, L. S., Parney, I. F., Pafundi, D. H., Brinkmann, D. H., Laack, N. N., Giannini, C., Burns, T. C., Kizilbash, S. H., Laramy, J. K., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox175 · Cited by 746
Self-citationRole of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance
Natarajan, K., Xie, Y., Baer, M. R., & Ross, D. D. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.01.002 · Cited by 405
Brain metastases as preventive and therapeutic targets
Steeg, P. S., Camphausen, K. A., & Smith, Q. R. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3053 · Cited by 363
Metadata
- Authors
- Agarwal, S., Sane, R., Gallardo, J. L., Ohlfest, J. R., & Elmquist, W. F.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2010-07
- Volume
- 334
- Issue
- 1
- Pages
- 147-155
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2137632859
- Cited by
- 255
- References
- 39
- FWCI
- 11.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.